Skip to content
Clinical Trials – home

Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II W Sosnowcu Sp. z o.o.

Verified siteinfoFast reply

Poland Ul. Marszalka Jozefa Pilsudskiego 9, 41-200 Sosnowiec, Poland

  • 10 trials recruiting
  • Dermatitis atopic · Hidradenitis · Juvenile psoriatic arthritis
  • Adults and children

About Specializations

Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II W Sosnowcu Sp. z o.o. in Sosnowiec, Poland specialises in clinical trials of conditions such as Dermatitis atopic, Hidradenitis, Juvenile psoriatic arthritis, Acne, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases – Dermatology

The Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II in Sosnowiec concentrates on clinical research for immune system diseases that manifest in the skin, with a primary focus on Atopic Dermatitis. The studies aim to assess new therapeutic approaches that could lessen disease severity and enhance patient wellbeing.

  • Evaluation of treatment efficacy using standardized severity scores
  • Monitoring of safety and tolerability over an extended period
  • Assessment of patient‑reported outcomes and quality of life

These investigations strive to deepen understanding of disease mechanisms and bring forward innovative options for long‑term management of skin‑related immune disorders.

Atopic Dermatitis Clinical Trials

The Dermatology department conducts trials involving adolescents with moderate‑to‑severe Atopic Dermatitis. The purpose is to determine whether a novel biologic therapy can more effectively reduce inflammation and improve skin condition compared with existing treatments.

  • Measurement of skin clearance using the Eczema Area and Severity Index
  • Long‑term follow‑up to evaluate sustained benefit
  • Exploration of impact on daily activities and sleep quality

This work complements broader efforts to address immune‑mediated skin diseases and aims to expand therapeutic choices for patients across Poland.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Marszalka Jozefa Pilsudskiego 941-200 SosnowiecPoland
Recruiting now
10 trials
Conditions studied
19
Partner status
Verified site

More sites in SosnowiecPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

34 clinical trials

Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:APG777
  • Sponsor:Apogee Therapeutics Inc.

Study on Cytisine for Quitting Nicotine E-Cigarettes and Tobacco in Motivated Individuals

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cytisine
  • Sponsor:University of Rzeszow

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Infants 6–23 Months with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Hidradenitis

Recruiting

A study to evaluate the effectiveness and safety of LAD328 in adults with moderate to severe hidradenitis suppurativa

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Almirall S.A.

Dermatitis+2

Recruiting

A study to evaluate the effectiveness of NAV-240 in adults with moderate-to-severe hidradenitis suppurativa

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IMB 101
  • Sponsor:Navigator Medicines Inc.

Hidradenitis

Recruiting

A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Almirall S.A.

Study on the Effects of Risankizumab and Adalimumab in Children with Active Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Psoriasis

Recruiting

Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Etanercept
  • Sponsor:Sun Pharmaceutical Industries Limited

Colitis ulcerative+2

Recruiting

Study on the Long-term Safety of Guselkumab for Children with Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Dermatitis atopic

Not yet recruiting

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Acne

Not yet recruiting

Safety and Efficacy Study of the Acne mRNA vaccine (mrt1800, mrt1801, mrt1802) in Adults 18‑45 Years with Moderate to Severe Acne

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Sponsor:Sanofi Pasteur Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.